Lv1
32 积分 2023-04-20 加入
四十五载开拓路 血脉相承启新穹
1天前
待确认
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
18天前
已完结
Incidence and spectrum of immune-related adverse events in nasopharyngeal carcinoma patients treated with immune checkpoint inhibitors
1个月前
已完结
Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma
1个月前
已完结
A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization
1个月前
已完结
.Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: a phase 2, multicenter, open‐label, single‐arm trial
1个月前
已完结
Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study
2个月前
已完结
Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group
2个月前
已完结
皖公网安备34019202002308
